MTOR and hepatocellular carcinoma: In the clinical practice, mTOR hyperactivity was observed in up to 45% patients with HCC, and patients with mTOR hyperactivity showed a tendency toward less differentiated tumors, early recurrence, and poor prognosis [7, 8].